Sports Medicine

SURFORCE® Amniotic Membrane Allograft

Value for Patients

Every second that we’re alive, the cells in our bodies are endlessly working to bring us back to a natural state of homeostasis or equilibrium. In sports injuries, patients rely upon Physical Medicine to allow their body’s systems to self-heal. SurForce® retains the native characteristics and inherent functionality of allograft tissues, including the ability to act as a protective cushion which aids in the process of regenerative medicine as an adjunct therapy to this process.

Our approach is to augment the body’s natural healing process to repair damaged musculoskeletal tissues, articular cartilage, meniscus, tendons, and ligaments. SurForce® is a cryopreserved amniotic membrane allograft injectable, which is available in a variety of sizes to accommodate specific injured regions. The efficacy of cryopreservation is well documented in several medical articles and can be referenced here.

If you are a Healthcare Provider please visit to get a detailed overview.

NEW Clinical Sports Medicine Update

Research - Data - Clinical Studies

Discover What Top Scientists are Saying

Discover what the top scientists, researchers and research universities are saying at The American Journal of Sports Medicine & National Center for Biotechnology Information Search database about the future of amniotic membrane products. Surforce® is our bioactive amnion product which is used for sports medicine.

Format: Abstract
Publish: April 2017 10.1177/0363546517697682.
Author information
  1. School of Medicine & Health Sciences, George Washington University, Washington, District of Columbia, USA.
  2. Department of Orthopaedic Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  3. Osiris Therapeutics Inc, Columbia, Maryland, USA.
Source: Research Article


Placenta has a long history of use for treating burns and wounds. It is a rich source of collagen and other extracellular matrix proteins, tissue reparative growth factors, and stem cells, including mesenchymal stem cells (MSCs). Recent data show its therapeutic potential for orthopaedic sports medicine indications.


To provide orthopaedic surgeons with an anatomic description of the placenta, to characterize its cellular composition, and to review the literature reporting the use of placenta-derived cells and placental tissue allografts for orthopaedic sports medicine indications in animal models and in humans.

STUDY DESIGN: Systematic review.


Using a total of 63 keyword combinations, the PubMed and MEDLINE databases were searched for published articles describing the use of placental cells and/or tissue for orthopaedic sports medicine indications. Information was collected on placental tissue type, indications, animal model, study design, treatment regimen, safety, and efficacy outcomes. Results were categorized by indication and subcategorized by animal model.


Outcomes for 29 animal studies and 6 human studies reporting the use of placenta-derived therapeutics were generally positive; however, the placental tissue source, clinical indication, and administration route were highly variable across these studies. Fourteen animal studies described the use of placental tissue for tendon injuries, 13 studies for osteoarthritis or articular cartilage injuries, 3 for ligament injuries, and 1 for synovitis. Both placenta-derived culture-expanded cells (epithelial cells or MSCs) and placental tissue allografts were used in animal studies. In all human studies, commercial placental allografts were used. Five of 6 human studies examined the treatment of foot and ankle pathological conditions, and 1 studied the treatment of knee osteoarthritis.


A review of the small number of reported studies revealed a high degree of variability in placental cell types, placental tissue preparation, routes of administration, and treatment regimens, which prohibits making any definitive conclusions. Currently, the clinical use of placenta is limited to only commercial placental tissue allografts, as there are no placenta-derived biological drugs approved for the treatment of orthopaedic sports medicine conditions in the United States. However, this review shows that the application of placental cells or tissue allografts appears to be safe and has potential to improve outcomes for orthopaedic sports medicine indications.

Format: Abstract
Publish: September 2016 10.1177/0363546515612750.
Author information
  1. Division of Sports Medicine and Shoulder Surgery, Rush University School of Medicine, Chicago, Illinois, USA
  2. Division of Sports Medicine and Shoulder Surgery, Rush University School of Medicine, Chicago, Illinois, USA
Source: Research Article


Amniotic membrane (AM)-derived products have been successfully used in ophthalmology, plastic surgery, and wound care, but little is known about their potential applications in orthopaedic sports medicine.


To provide an updated review of the basic science and preclinical and clinical data supporting the use of AM-derived products and to review their current applications in sports medicine.


Systematic review.


A systematic search of the literature was conducted using the Medline, EMBASE, and Cochrane databases. The search term amniotic membrane was used alone and in conjunction with stem cell, orthopaedic, tissue engineering, scaffold, and sports medicine.


The search identified 6870 articles, 80 of which, after screening of the titles and abstracts, were considered relevant to this study. Fifty-five articles described the anatomy, basic science, and nonorthopaedic applications of AM-derived products. Twenty-five articles described preclinical and clinical trials of AM-derived products for orthopaedic sports medicine. Because the level of evidence obtained from this search was not adequate for systematic review or meta-analysis, a current concepts review on the anatomy, physiology, and clinical uses of AM-derived products is presented.


Amniotic membranes have many promising applications in sports medicine. They are a source of pluripotent cells, highly organized collagen, antifibrotic and anti-inflammatory cytokines, immunomodulators, and matrix proteins. These properties may make it beneficial when applied as tissue engineering scaffolds, improving tissue organization in healing, and treatment of the arthritic joint. The current body of evidence in sports medicine is heavily biased toward in vitro and animal studies, with little to no human clinical data. Nonetheless, 14 companies or distributors offer commercial AM products. The preparation and formulation of these products alter their biological and mechanical properties, and a thorough understanding of these differences will help guide the use of AM-derived products in sports medicine research.

You're here because you want the facts

Surgenex® created SurForce® "an injectable allograft" using our patent pending process to produce it as a minimally manipulated product which conforms to the regulations and the FDA’s definition found in HTC/P 361 products in accordance with FDA Article 21 CFR Part 1271. Following these standards allows Surgenex® to sell approved allograft products with confidence to Healthcare Providers; if you are a Healthcare Provider please visit to get a detailed overview.

Surgenex Products helps women
SurForce® is an injectable flowable Amniotic Membrane Allograft, derived from a donated placenta via C-section delivery.
Within the Placenta the Amniotic Membrane supplies an abundant resource of regenerative cellular tissues, is surgically dissected and processed using our proprietary Excellion® process. SurForce® is manufactured using this patented process to remove the chorion, filter out excess cellular debris, and purify the amniotic membrane allograft. The results yield the highest concentration of amniotic membrane on the market today.

SURGENEX® conducts a 14-day sterility tests performed by a third-party laboratory to confirm our products are free of bacterial and fungal contaminants. These safety barriers verify that SurForce® is the cleanest and safest amniotic membrane tissue allograft product in the industry.

DONOR INFORMAITON: SurForce® is thoroughly tested for safety in clinical procedures. Our donor serology test panel is the most extensive in the industry, testing for several potential pathogens that could be missed by less extensive testing observed in competitive industry products.

Every Donor-placenta is regulated through the Food and Drug Administration and is deemed qualified for transplantation by our authorized recovery agency. The recovery agency provides a detailed medical history and extensive medical background screening of all placenta Donors. All donor recoveries meet and adhere to the FDA regulations requisite to HCT/P recovery and the screening and testing of the tissue donor as verified through laboratory testing. SURGENEX® requires each donor placenta to be tested beyond the FDA’s required testing panel, as we value most importantly, the safety of our products.
SurForce® contains concentrated amniotic membrane tissues that creates a protective cushion. Since amniotic membrane is naturally immune-evasive, there have been no adverse reactions reported.
SurForce® can be used for a myriad of conditions, refer to a Medical Provider today if you are a candidate. Amniotic membrane® also lacks the cell surface receptor HLA-DR, which gives it the unique ability to avoid triggering immune responses. This missing receptor gives SurForce®the opportunity to graft damaged tissue areas without an adverse response.
Surgenex Products helps men
As with any condition or injury, a patient must consult with their Primary Care Physician or Healthcare Provider for medical advice. If you feel you are a candidate for SurForce® injections, schedule a visit with your Provider to talk about the benefits and outcomes of amniotic membrane treatments.
On your initial visit, you or your Provider may discuss your medical history, chief complaints, and any alternative treatments you have participated in the past to treat your current conditions. Initial or subsequent visits may also include a review of findings to discuss diagnostic imaging reports, treatment options, and a treatment plan. Each patient may present with variables that are unique to their condition, therefore, each case may be customized to each individual. Candidates for SURFORCE® injections may follow the recommendations given by their Provider. Providers may give dosage and frequency recommendations based on the patient’s Medical History, Etiology, Diagnosis and Prognosis.
If SurForce® is right for you, seeking out an experienced licensed Medical Provider of regenerative medicine ensures you access to the industry’s leading allograft injectable. Ask your Provider today if they are using SurForce®, or ask for a referral to a nearby clinic utilizing SurForce®.

Top Questions From Patients


SurForce® is a cryopreserved injectable derived from Amniotic Membrane Tissue.


For patient outcomes and success stories, please contact the SurForce® Healthcare Provider nearest you. You can also peruse through our patient testimonial section here.


The easiest way to get started is by filling out the contact questionnaire found here. We can identify the nearest SurForce® Providers in your area. A Provider will contact you shortly to address any of your questions or concerns. Surgenex distributes its products exclusively to verified medical facilities.


Our bodies naturally degenerate over time. The regenerative processes that were once vibrant and energetic in our youth become slower and impeded as we age.


Your Provider may or may not recommend post-treatment rehabilitation. This decision will depend heavily upon the injured area and its pathology/etiology, as well as your current physical health status. Patients should work with their Healthcare Provider to determine if rehab will be necessary and/or beneficial.


Depending on the etiology, pathology, and severity of the chief complaint, each patient will be unique. Healthcare Providers can gather subjective and objective information such as patient history, orthopaedic examinations, diagnostic imaging, and lab results to assess and determine the patient’s needs. Based on these findings, Healthcare Providers can specify an appropriate treatment plan. Costs associated with specific procedures may depend on these variables. For specifics, contacting the nearest Provider of SurForce® for a consultation is recommended.


Depending on the region, or if there are multiple locations needing an injection, the treatment procedure can be administered during a standard office visit. Specific times may vary depending on factors inherent to the complications of the patient’s needs. The application of the treatment is non-surgical, and requires no pre-treatment preparation time.


There are several advantages to using Amniotic Membrane tissues rather than invasive medical procedures. Unlike pharmaceuticals and lengthy surgical procedures, to date no negative side effects have been reported with amniotic membrane allografts.


As with any treatment modality in Healthcare, there is always an inherent risk. It is understood from the research, that no adverse side effects are evident. Furthermore, SurForce® maintains the highest standards of safety in our industry, exceeding the FDA’s minimum safety requirements.


Surgenex uses the Excellion® Process to produce SurForce®. This patented process is a highly manual and surgical process that isolates the amniotic membrane layer of the placenta. No other portion of the placenta is utilized.


Research shows that amniotic membrane tissue allografts contain extracellular matrices including growth factors, anti-fibrotics , anti-microbials, are immune-evasive, and have anti-inflammatory properties.

Research also shows it has the potential to repair articular cartilage. Please peruse our Research section here for research articles related to the incredible benefits of amniotic membrane tissue allografts.

Common Clinical Applications for Treatment

*The use of amniotic tissue in orthopaedic surgery has increased in recent years. source..
Orthopaedics Surgery Increased
*The use of amniotic tissue products in sports medicine has increased in recent years source..
Sports Medicine Treatment Increased
Podiatry Treatment Increased
*The use of amniotic tissue products in podiatry has increased in recent years source..

Amniotic Membrane Tissue Allografts Features

Features SurForce PRP BMA
Help Support YES Yes X
Help Protect YES X X
Help Cushion YES X X
15 min 1-2 hrs 2-4 hrs

SurForce® Cryopreserved
Amniotic Membrane
Allograft Injections

The Challenges Sports Orthopaedists Face Today

Cardiology research is proving that sitting is the new smoking. Increasingly, the general public are becoming more aware of the profound benefits to living a dynamic and active lifestyle. However, Patients that suffer from histories of injury and disease are finding it increasingly difficult to achieve their personal goals. In an effort to maintain physical activity, even into the latter stages of life, people are seeking more innovative and alternative means of alleviating these ailments.

Orthopaedic specialists are progressively being approached to utilize their strategies to ​help patients achieve their goals and enhance their overall quality of life. Moreover, people who currently cannot take part in either recreational ​or ​aggressive sports are searching for treatment options to get them back into normal activities of daily living​ or mild forms of​ exercise both safely and effectively. Today's research now supports the utilization of amniotic membrane tissue products in the field of orthopaedics, which aids the augmentation of the body’s natural healing process for many musculoskeletal conditions.

Discover More Orthopaedic Treatments & Definitions*







*As with any condition or injury, a patient must consult with their Primary Care Physician or Healthcare Provider for medical advice.

Download SurForce® Brochure